Carmell Therapeutics Corporation (CTCX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Carmell Therapeutics Corporation (CTCX) has a cash flow conversion efficiency ratio of 0.198x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-752.95K) by net assets ($-3.81 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Carmell Therapeutics Corporation defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Carmell Therapeutics Corporation - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how Carmell Therapeutics Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Carmell Therapeutics Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Carmell Therapeutics Corporation ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Scisparc Ltd
NASDAQ:SPRC
|
-0.442x |
|
ASN Broker Public Company Limited
BK:ASN
|
0.027x |
|
Mountain Province Diamonds Inc
TO:MPVD
|
2.361x |
|
BOCANA RESOURCES CORP.
F:VC1
|
N/A |
|
Joe Holding Bhd
KLSE:7096
|
-0.016x |
|
PAVmed Inc
NASDAQ:PAVM
|
-0.035x |
|
Sfinks Polska S.A.
WAR:SFS
|
-0.024x |
|
Cann Group Ltd
AU:CAN
|
0.000x |
Annual Cash Flow Conversion Efficiency for Carmell Therapeutics Corporation (2021–2024)
The table below shows the annual cash flow conversion efficiency of Carmell Therapeutics Corporation from 2021 to 2024. For the full company profile with market capitalisation and key ratios, see Carmell Therapeutics Corporation (CTCX) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-4.71 Million | $-4.39 Million | 0.931x | +376.10% |
| 2023-12-31 | $24.75 Million | $-8.35 Million | -0.337x | -471.78% |
| 2022-12-31 | $-37.79 Million | $-3.43 Million | 0.091x | +128.03% |
| 2021-12-31 | $-29.58 Million | $-1.18 Million | 0.040x | -- |
About Carmell Therapeutics Corporation
Carmell Corporation operates as a bio-aesthetics company. The company utilizes Carmell Secretome to support skin and hair health. Its Carmell Secretome consists of growth factors and proteins extracted from allogeneic human platelets sourced from tissue banks. The company also developed a microemulsion formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on … Read more